AgroSavfe appoints Patrice Sellès as new Chief Executive Officer and further strengthens leadership team
- Patrice brings over 20 years of leadership experience in the Food and Crop Protection sector
- Luc Maertens appointed Chief Operations Officer
- Significantly strengthened AgroSavfe’s leadership team to further support accelerated growth of the Company
GHENT, Belgium, July 02, 2019 (GLOBE NEWSWIRE) -- AgroSavfe NV, a rapidly growing and transformative AgTech company developing next generation AGROBODY™-based biocontrols, today announces the appointment of Patrice Sellès as new Chief Executive Officer (CEO). In addition, Luc Maertens has been appointed Chief Operations Officer (COO).
Patrice joins AgroSavfe from Syngenta, a leading agriculture company, where he spent more than 17 years in various international executive leadership and scientific positions, as Global Head R&D Strategic Portfolio and Performance, but also as venture investment manager. Patrice held his positions both in Europe and in the US.
Building on the proprietary AGROBODY Foundry™ Platform, Luc Maertens will head the full development of the rapidly expanding proprietary product pipeline as Chief Operations Officer. In this position, Luc will lead the coordination and execution of the Company’s programs from product design through to development and regulatory submissions as well as the commercial scale manufacturing.
Lieven De Smedt, Chairman of the Board of Directors, commented: “We are very pleased that Patrice is joining us as new CEO to bring AgroSavfe to the next level in the international markets. He thoroughly understands the Agro Industry dynamics thanks to his 20-year track record in various leadership roles, including portfolio and investment strategy development and execution, and business development. His expertise will be invaluable as we enter an important new phase and are starting to prepare the launch of our first product, expected in 2022.”
Patrice Sellès, CEO of AgroSavfe, said: “I am thrilled to have been offered the opportunity to lead AgroSafve at this important stage. Over the past few years, the team has de-risked a unique technology platform and developed a promising pipeline and I am excited to build on this success with our fantastic team in Ghent. I look forward to engaging with our stakeholders and supporting the company in becoming a strong and substantial business for the long term, addressing the many challenges currently facing worldwide agriculture and food production.”
The growing demand for healthy, safe and sustainable food has increasingly imposed restrictions on agricultural practices. Therefore, improving food production efficiency in a sustainable way, while safeguarding the environment and its natural resources, is essential.
AgroSavfe has the ambition to contribute to a sustainable production of safe and healthy food. The Company is focused on the discovery, development and commercialization of effective and safe biocontrols to tackle plant pests and diseases using its ground-breaking, scalable, proprietary AGROBODY Foundry™ Platform.
AgroSavfe’s products are a novel class of biocontrols based on AGROBODY™ bioactive proteins that effectively and selectively target pests’ and pathogens’ essential molecules. AGROBODY™ bioactives combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.
Based on its unique AGROBODY™ platform, AgroSavfe has built a versatile product pipeline against key pests and diseases, with the first product expected to enter the US market in 2022.
The Company was founded in 2013 as a spin-off from the VIB (Flemish Institute for Biotechnology) and is based in the biotech cluster in Ghent, Belgium. More information can be found on www.agrosavfe.com.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
FRO - Invitation to Q3 2019 Results Conference Call and Webcast19.11.2019 13:16:00 CET | Press release
Frontline Ltd.’s preliminary third quarter 2019 results will be released on Wednesday November 27 2019, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontline.bm ahead of the conference call. In order to attend the conference call you may do one of the following: a. Webcast Go to the Investor Relations section at www.frontline.bm and follow the “Webcast” link. b. Conference Call Participant dial-in telephone numbers: Norway +47 2156 3162 Norway toll free 800 10392 UK +44 (0) 203 009 5710 UK Toll Free 0 800 376 7425 USA +1 917 720 0178 USA Toll Free 866 869 2321 Conference ID 5598374 Participants will be asked for their full name & Conference ID. A Q&A session will be held after the teleconference/webcast. Information on how to submit questions will be given at the beginning of the session. The presentation material which will be used in th
Oasmia offentliggör prospekt i samband med företrädesemission om cirka 399 MSEK samt uppdaterad information som återfinns i prospektet19.11.2019 13:00:00 CET | Pressemelding
EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER ÄN VAD SOM FÖLJER AV SVENSK RÄTT. Styrelsen i Oasmia Pharmaceutical AB (“Oasmia” eller ”Bolaget”) meddelande den 11 november 2019 om genomförandet av en nyemission av aktier med företrädesrätt för Oasmias befintliga aktieägare om cirka 399 MSEK ("Företrädesemissionen"). Bolaget har med anledning av Företrädesemissionen upprättat ett prospekt som idag godkänts och registrerats av Finansinspektionen. Offentliggörande av prospekt För fullständig information om Företrädesemissionen hänvisas till det prospekt som upprättats av Bolaget samt idag godkänts och registrerats av Finansinspektionen per dagens datum.
Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus19.11.2019 13:00:00 CET | Press release
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Oasmia Pharmaceuticals AB (publ). See the section “IMPORTANT INFORMATION” below. The board of Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) announced on 11 November 2019 to carry out a new issue of shares with preferential rights for Oasmia’s shareholders of approximately SEK 399 million (the “Rights Issue”). As a result of the Rights Issue, the Company has prepared a prospectus, which has been approved and registered by the Swedish Financial Supervisory Authority today. Publication of the prospectus For complete information on the Rights Issue, refer to the prospectus that has been prepared by Oasmia as well as appro
Medtronic Reports Second Quarter Financial Results19.11.2019 12:45:00 CET | Press release
Revenue of $7.7 Billion Increased 3.0% Reported and 4.1% Organic GAAP Diluted EPS of $1.01; Non-GAAP Diluted EPS of $1.31 Cash Flow from Operations of $1.9 Billion Grew 61%; Free Cash Flow of $1.6 Billion Grew 66% Company Raises FY20 EPS Guidance DUBLIN, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2020, which ended October 25, 2019. The company reported second quarter worldwide revenue of $7.706 billion, an increase of 3.0 percent as reported or 4.1 percent on an organic basis, which adjusts for a $97 million negative impact from foreign currency and a $16 million contribution from the company’s acquisition of Titan Spine, which is reported in the Spine division in the Restorative Therapies Group. As reported, second quarter GAAP net income and diluted earnings per share (EPS) were $1.364 billion and $1.01, respectively. As detailed in the financial schedules included through the link at the end of t
Avenir LNG collaborates with Golar Power on developing small-scale LNG distribution in Brazil19.11.2019 12:00:00 CET | Press release
London, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Avenir LNG Limited (“Avenir”) wishes to announce that it will collaborate with Golar Power Limited (“Golar Power”) in developing the small-scale LNG market in Brazil. Avenir’s second 7,500 cbm LNG Carrier will be used to deliver LNG to various ports across Brazil upon delivery. The vessel will also offer ship-to-ship bunkering capability as part of Avenir’s global multi-nodal bunkering solution; adding to the Colombian, Mediterranean and Malaysian nodes which the company currently offers. Commenting on the collaboration with Golar Power, Andrew Pickering, Chief Executive Officer of Avenir LNG Limited, said, “This is another step in our strategy where we are working closely with a shareholder in leveraging its FSRU platform to develop small-scale LNG distribution and bunkering in key developing markets.” Commenting on the collaboration with Avenir LNG, Eduardo Antonello, Chief Executive Officer of Golar Power Limited, said, “Accessing small-scal
Conversion factor for Exchange offer in SGB IL 3102 2019-11-1919.11.2019 11:03:00 CET | Press release
2019-11-19 Conversion factor SGB IL 3102/3109; 0.8381954 The conversion factor of SGB IL 3102/3109 indicates the amount of SGB IL 3102 that the SNDO will buy back for each SGB IL 3109 issued in the switch auction at November 19, 2019. For further information, please contact: The funding desk + 46 8 613 4780 Funding@riksgalden.se